Holen Sie sich die Stockscreener-App
0.2897
0.10%
-0.0003
Schlusskurs vom Vortag:
$0.29
Offen:
$0.2836
24-Stunden-Volumen:
1.04M
Relative Volume:
0.16
Marktkapitalisierung:
$5.04M
Einnahmen:
$12.99M
Nettoeinkommen (Verlust:
$-17.41M
KGV:
-0.0881
EPS:
-3.29
Netto-Cashflow:
$-11.73M
1W Leistung:
+20.21%
1M Leistung:
+21.26%
6M Leistung:
-62.86%
1J Leistung:
-96.64%
1-Tages-Spanne:
$0.264
$0.2898
1-Wochen-Bereich:
$0.2022
$0.3255
52-Wochen-Spanne:
$0.138
$10.80
Aptevo Therapeutics Inc Stock (APVO) Company Profile
Firmenname
Aptevo Therapeutics Inc
Sektor
Branche
Telefon
206-838-0500
Adresse
2401 4TH AVE., SEATTLE, WA
Vergleichen Sie APVO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| APVO | 0.2897 | 5.04M | 12.99M | -17.41M | -11.73M | -3.29 |
| VRTX | 450.27 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.65 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.61 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.57 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.17 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2018-11-05 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-10-05 | Fortgesetzt | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc Aktie (APVO) Neueste Nachrichten
First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies - AccessWire
Aptevo's AML Drug Shows 90% Cancer Reduction in Early Trial Results | APVO Stock News - StockTitan
Aptevo Therapeutics (NASDAQ:APVO) Coverage Initiated at StockNews.com - Defense World
Armistice Capital, LLC's Strategic Acquisition of Aptevo Therape - GuruFocus.com
Alligator Bioscience reports positive results for APV-527 in Phase 1 study - Marketscreener.com
Alligator Bioscience announces positive results for APV-527 - Marketscreener.com
First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial - AccessWire
Aptevo's Cancer Drug Shows Promise: 56% of Patients Achieve Disease Stability in Phase 1 | APVO Stock News - StockTitan
Hudson Bay Capital Management LP's Strategic Acquisition in Aptevo Therapeutics Inc - GuruFocus.com
Aptevo Therapeutics Inc (APVO) Quarterly 10-Q Report - Quartz
Aptevo Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update - AccessWire
Aptevo Therapeutics (NASDAQ:APVO) Coverage Initiated by Analysts at StockNews.com - Defense World
Alligator Bioscience to present positive data for mitazalimab at SITC - Marketscreener.com
Aptevo Therapeutics Inc (NASDAQ: APVO) Has Great Upside Potential - Stocks Register
Aptevo Therapeutics (NASDAQ:APVO) Now Covered by Analysts at StockNews.com - Defense World
Alligator Bioscience presents positive interim data from Phase 1 study - Marketscreener.com
Aptevo Therapeutics and Alligator Bioscience to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024 - AccessWire
Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Update - Defense World
Aptevo Therapeutics secures shareholder nod for key proposals By Investing.com - Investing.com South Africa
Aptevo Therapeutics secures shareholder nod for key proposals - Investing.com India
Why Spirit Airlines Shares Are Trading Higher By Around 44%; Here Are 20 Stocks Moving Premarket(SAVE) - Benzinga
There is no doubt that Aptevo Therapeutics Inc (APVO) ticks all the boxes. - SETE News
Aptevo Therapeutics Inc (NASDAQ: APVO) – An Analysis Is What You Need - Stocks Register
Stock Market Recap: Aptevo Therapeutics Inc (APVO) Concludes at 0.15, a -2.87 Surge/Decline - The Dwinnex
A stock that deserves closer examination: Aptevo Therapeutics Inc (APVO) - US Post News
APVO stock plunges to 52-week low of $0.14 amid market challenges - Investing.com Australia
APVO stock plunges to 52-week low of $0.14 amid market challenges By Investing.com - Investing.com South Africa
You might want to take a look at Aptevo Therapeutics Inc (APVO) now - SETE News
APVO’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Gaining Ground: Aptevo Therapeutics Inc (APVO) Closes Lower at 0.16, Down -2.60 - The Dwinnex
Aptevo Therapeutics Inc (APVO) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News
Aptevo Therapeutics (NASDAQ:APVO) Research Coverage Started at StockNews.com - Defense World
Research Analysts’ Updated EPS Estimates for October 6th (APVO, CNP, FDX, FLNT, FRD, GALT, HOPE, KBR, LSXMK, NVGS) - Defense World
Aptevo Therapeutics Inc (APVO)’s stock decline to 0.16 per share - US Post News
APVO Stock Update: Aptevo Therapeutics Inc’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle
Financial Metrics Check: Aptevo Therapeutics Inc (APVO)’s Ratios for Trailing Twelve Months - The Dwinnex
Certain Restricted Stock Units of Aptevo Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 30-SEP-2024. - Marketscreener.com
Aptevo Therapeutics (NASDAQ:APVO) Stock Quotes, Forecast and News Summary - Benzinga
Aptevo Therapeutics (NASDAQ:APVO) Now Covered by StockNews.com - Defense World
Aptevo Therapeutics Inc Inc. (APVO) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Down 78.8% in September - Defense World
Short Interest in Advantest Co. (OTCMKTS:ATEYY) Declines By 85.7% - MarketBeat
Applied Therapeutics (NASDAQ:APLT) Stock Price Up 5.2% - Defense World
Astria Therapeutics (NASDAQ:ATXS) Shares Gap Down to $12.50 - MarketBeat
DRW Securities LLC Invests $117,000 in Patterson-UTI Energy, Inc. (NASDAQ:PTEN) - Defense World
Gabelli Funds LLC Raises Stake in Aptiv PLC (NYSE:APTV) - Defense World
Aptevo Therapeutics Inc. (NASDAQ:APVO) to Post Q3 2024 Earnings of ($0.57) Per Share, Roth Capital Forecasts - Defense World
Aptiv PLC stock rises Tuesday, outperforms market - MarketWatch
Logos Global Management LP Sells 750,000 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Patterson-UTI Energy (NASDAQ:PTEN) Shares Down 3.5% - Defense World
Finanzdaten der Aptevo Therapeutics Inc-Aktie (APVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):